These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28221219)

  • 1. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.
    Carlsson SV; Roobol MJ
    Curr Opin Urol; 2017 May; 27(3):198-204. PubMed ID: 28221219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy.
    Kotb AF; Spaner S; Crump T; Hyndman ME
    World J Urol; 2018 Dec; 36(12):2021-2025. PubMed ID: 29808301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
    Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population.
    Hsieh PF; Li WJ; Lin WC; Chang H; Chang CH; Huang CP; Yang CR; Chen WC; Chang YH; Wu HC
    World J Urol; 2020 May; 38(5):1207-1214. PubMed ID: 31440806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MRI for prostate cancer detection: performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL.
    Petrillo A; Fusco R; Setola SV; Ronza FM; Granata V; Petrillo M; Carone G; Sansone M; Franco R; Fulciniti F; Perdonà S
    J Magn Reson Imaging; 2014 May; 39(5):1206-12. PubMed ID: 25006636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
    Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.
    Ukimura O; Coleman JA; de la Taille A; Emberton M; Epstein JI; Freedland SJ; Giannarini G; Kibel AS; Montironi R; Ploussard G; Roobol MJ; Scattoni V; Jones JS
    Eur Urol; 2013 Feb; 63(2):214-30. PubMed ID: 23021971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
    Jambor I; Kähkönen E; Taimen P; Merisaari H; Saunavaara J; Alanen K; Obsitnik B; Minn H; Lehotska V; Aronen HJ
    J Magn Reson Imaging; 2015 May; 41(5):1394-404. PubMed ID: 24956412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
    Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
    Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
    McDonald ML; Parsons JK
    Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
    Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
    J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
    Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
    Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
    Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.